PPARG and Alzheimer disease: Therefore, from a therapeutic standpoint, detailed preclinical ARB treatment studies are required with in-depth pharmacokinetic analyses in order to determine whether any of the currently available ARBs are optimal candidates for the treatment of AD, or if there may be more therapeutic potential in developing a new ARB that is optimized for PPARγ activating properties and brain penetrance.